Pneumonia vaccine - USA

Decision on IPR: Mar 13, 2019

AIA Review	Filing Date	Institution Date	Petitioner	US Patent	Respondent	Final Written Decision
IPR2017-02131	09/19/2017	03/22/2018	Merck	9,492,559	Pfizer Inc.	claims 1–10, 16–19, & 38–45 are  unpatentable
IPR2017-02132	09/19/2017	03/22/2018	Merck	9,492,559	Pfizer Inc.	claims 1–10, 16–19, and 38–45 are unpatentable
IPR2017-02136	09/19/2017	03/22/2018	Merck	9,492,559	Pfizer Inc.	claims 11–15 and 20–37 are unpatentable
IPR2017-02138	09/19/2017	03/22/2018	Merck	9,492,559	Pfizer Inc.	claims 11–15 and 20–37 are unpatentable

Previously Merck also filed other IPRs (IPR2018-00187 & IPR2018-00188) on 11/20/2017 of which IPR’187 was instituted & IPR’188 was denied by PTAB.

US 9,492,559 (Pfizer Inc.; Exp: Jan 15, 2035) :

1. An immunogenic composition comprising a Streptococcus pneumoniae serotype 22F glycoconjugate, wherein the glycoconjugate has a molecular weight of between 1000 kDa and 12,500 kDa and comprises an isolated capsular polysaccharide from S. pneumoniae serotype 22F and a carrier protein, and wherein a ratio (w/w) of the polysaccharide to the carrier protein is between 0.4 and 2.